Obesity is associated with genetic variants that alter dopamine availability
Related Experiment Video
Updated: Aug 8, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
A C Need1, K R Ahmadi, T D Spector
1Department of Biology, University College London, The Darwin Building, Gower Street, London WC1E 6BT.
Abstract:
Human and animal studies have implicated dopamine in appetite regulation, and family studies have shown that BMI has a strong genetic component. Dopamine availability is controlled largely by three enzymes: COMT, MAOA and MAOB, and by the dopamine transporter SLC6A3, and each gene has a well-characterized functional variant. Here we look at these four functional polymorphisms together, to investigate how heritable variation in dopamine levels influences the risk of obesity in a cohort of 1150, including 240 defined as obese (BMI > or = 30). The COMT and SLC6A3 polymorphisms showed no association with either weight, BMI or obesity risk. We found, however, that both MAOA and MAOB show an excess of the low-activity genotypes in obese individuals (MAOA:chi2= 15.45, p = 0.004; MAOB:chi2= 8.05, p = 0.018). Additionally, the MAOA genotype was significantly associated with both weight (p = 0.0005) and BMI (p = 0.001). When considered together, the 'at risk genotype'--low activity genotypes at both the MAOA and MAOB loci--shows a relative risk for obesity of 5.01. These results have not been replicated and, given the experience of complex trait genetics, warrant caution in interpretation. In implicating both the MAOA and MOAB variants, however, this study provides the first indication that dopamine availability (as opposed to other effects of MAOA) is involved in human obesity. It is therefore a priority to assess the associations in replication datasets.
Related Concept Videos
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Obesity
Type II Diabetes I: Introduction
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

